Citius Oncology, Inc (CTOR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Citius Oncology, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Citius Oncology, Inc (CTOR) has returned -38.01% so far this year and -33.34% over the past 12 months.

Based on dividend-adjusted daily data since Dec 8, 2022, CTOR's average daily return is +0.13%, while the average monthly return is +2.47%. At this rate, your investment would double in approximately 2.4 years.

Historically, 60% of months were positive and 40% were negative. The best month was Jun 2025 with a return of +383.3%, while the worst month was Aug 2024 at -83.6%. The longest winning streak lasted 18 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CTOR closed higher 34% of trading days. The best single day was Aug 5, 2024 with a return of +192.9%, while the worst single day was Aug 13, 2024 at -92.1%.

Citius Oncology, Inc has an annualized alpha of 41.96%, beta of -0.21, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 09, 2022.

• This stock participated in 220.58% of S&P 500 Index downside but only -111.51% of its upside — more exposed to losses than it benefited from rallies.
• Beta of -0.21 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CTOR ranks 38 for risk / return — below 38% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Citius Oncology, Inc (CTOR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Citius Oncology, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Citius Oncology, Inc was 98.78%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current Citius Oncology, Inc drawdown is 98.47%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Citius Oncology, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Citius Oncology, Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.